Tada T, Matono T, Kumada T. Response to the Letter Regarding "Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial". J Gastroenterol Hepatol 2026 Aug 6. doi: 10.1111/jgh.70654.
PMID: 42563422